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in any medium, provided the original work is properly citeHoming of colorectal cancer (CRC) cells to the liver is a non-random process driven
by a crosstalk between tumour cells and components of the host tissue. Here we
report the isolation of a liver metastasis-specific peptide ligand (CGIYRLRSC) that
binds a complex of E-cadherin and a6 integrin on the surface of CRC cells. We
identify angiopoietin-like 6 protein as a peptide-mimicked natural ligand enriched
in hepatic blood vessels of CRC patients. We demonstrate that an interaction
between hepatic angiopoietin-like 6 and tumoural a6 integrin/E-cadherin drives
liver homing and colonization by CRC cells, and that CGIYRLRSC inhibits liver
metastasis through interference with this ligand/receptor system. Our results
indicate a mechanism for metastasis whereby a soluble factor accumulated in
normal vessels functions as a specific ligand for circulating cancer cells. Consis-
tently, we show that high amounts of coexpressed a6 integrin and E-cadherin in
primary tumours represent a poor prognostic factor for patients with advanced
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d.INTRODUCTION
Up to 25% of patients diagnosed with colorectal cancer (CRC)
present with liver metastases; in a further 30–40% of cases,
metastases will develop within 2 years from the resection of the
primary tumour (Parkin et al, 2005). Patients with operable
liver-confined lesions might be cured by resection (Tomlinson
et al, 2007), but surgical cures are relatively rare in this setting.
Most patients with metastatic disease are candidates for
systemic chemotherapy to palliate symptoms and, potentially,
to downstage tumours to a resectable status (Adam et al, 2004).
Without treatment, the median survival of patients with liver
metastases is 6–8 months, and 5-year survival rates are <5%
(Wagner et al, 1984). The introduction of targeted biodrugs, e.g.
Bevacizumab (Hurwitz et al, 2004), Cetuximab (Jonker et al,
2007) and Panitumumab (Saltz et al, 2006), has prolonged the
median survival expectancy up to 24 months.
However, a pharmacological cure is still anecdotal, and
hepatic metastasis remains the central clinical challenge in the
management of CRC. It is now clear that only new classes ofs is an open access article under
se, distribution and reproduction
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2drugs that attack new targets will substantially improve the
state of the art for CRC care (Saltz, 2008). It has long been
recognized that several proteins integrate their action during
the natural history of metastatic CRC (Fearon & Vogelstein,
1990; Vogelstein et al, 1988); in addition to alterations in
tumour cells, a pivotal contribution to metastatic onset comes
from components of the host tissue and stroma (Hanahan &
Weinberg, 2011). Based on these assumptions, insights into
the molecular mechanisms underlying this disease have begun
to emerge through genomics and proteomics (Koh et al, 2008;
Nibbe et al, 2009). However, the fact that mRNA levels are not
necessarily correlated with protein amounts confers limitations
for gene expression analyses; alternatively, proteomics is time-
consuming and expensive, features that render its routine use
difficult.
We here report an alternative approach, based on screening
combinatorial peptide libraries ex vivo on liver metastases
obtained from CRC patients during surgery. This allowed
selecting short peptide motifs as specific ligands for the
microenvironment of human liver metastasis. We combined
bioinformatics, genetics and biochemistry tools to uncover
candidate proteins with potential ligand (i.e. peptide-like) or
receptor (i.e. peptide-binding) properties. This approach led
to the identification of angiopoietin-like 6, a6 integrin, and
E-cadherin as key molecular interactors.
Angiopoietin-like 6 is a secreted glycoprotein; the corre-
sponding mRNA has been detected exclusively in the liver in
humans (Kim et al, 2000). Although it shares a common
structure with other members of the family, angiopoietin-like 6
does not bind the Tie1 or Tie2 receptors (Oike et al, 2005).
Angiopoietin-like 6 regulates angiogenesis by (i) prevention of
endothelial cell apoptosis (Kim et al, 2000), (ii) induction of
endothelial cell migration and vascular leakiness (Oike et al,
2004) and (iii) enhancement of blood flow (Urano et al, 2008).
There is evidence that RGD-binding integrins might be involved
in angiopoietin-like 6-mediated cell adhesion and migration
(Zhang et al, 2006), although a direct interaction with integrins
was not described.
Alpha 6 Integrin, complexed with the b1 or b4 subunit, is a
receptor for laminin (Humphries et al, 2006), with a role in
angiogenesis (Gonzalez et al, 2002) and cancer progression
(Rabinovitz et al, 2001) through both direct and indirect
mechanisms. Among these, (i) relocalization of a6b4 integrin
from hemidesmosomes to the edge of lamellipodia and filopodia
has been related to a functional switch from adhesion to
migration (Germain et al, 2009; Mercurio et al, 2001), (ii)
interaction of a6b4 integrin with tyrosine-kinase receptors has
been shown to amplify pro-invasive signals (Bertotti et al, 2005;
Guo et al, 2006; Kawano et al, 2010), (iii) a6b1 and a6b4
integrins mediate CRC cell binding to hepatocytes (Enns et al,
2004) and extravasation during the onset of metastasis
(Robertson et al, 2009), although the molecular mechanisms
remain to be elucidated.
E-cadherin is a well-described oncosuppressor whose
expression in the primary tumour counteracts cell detachment
and is therefore associated with a better outcome (Christofori,
2003). Decreased production of E-cadherin is one of the central 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.events underlying epithelial–mesenchymal transition and
carcinoma progression in response to cellular events such as
(i) acquisition of loss-of-function mutations and loss-of-hetero-
zygosis for the mutant allele (Ilyas et al, 1997), (ii) transcrip-
tional or epigenetic repression (Natalwala et al, 2008) and (iii)
aberrant cellular localization (Elzagheid et al, 2006). In contrast,
the role of E-cadherin in late stages of cancer progression needs
further characterization. Remarkably, different reports show
that both mRNA and protein expression are regained in a subset
of liver metastases (Wells et al, 2008), and increased levels of
E-cadherin have been detected in liver metastases in comparison
to metastases in other sites (Elzagheid et al, 2006).RESULTS
Peptide ligands specific for the microenvironment of human
liver metastases secondary to CRC display conserved amino
acid motifs
We isolated heterogeneous cell populations by tissue fractiona-
tion of human liver metastases immediately after surgical
removal, and we used cells extracted from matching, grossly
normal livers as negative controls. We screened phage-
displayed random peptide libraries with the general arrange-
ments CX7C, CX9C, and CX3CX3CX3C (C¼Cys and X¼ any aa)
on a panel of tumour/normal paired samples in 22 independent
biopanning experiments. A total of 265 phage clones were
recovered, purified and DNA-sequenced (Scott & Smith, 1990;
Smith & Scott, 1993). Analysis of the corresponding peptides
revealed 203 unique metastasis-binding sequences. The tripep-
tide LRS was the most represented, being shared by23% of the
clones (Fig 1A).
The enrichment for specific sequences among the metastasis-
binding peptides was suggestive of a role as a relevant ligand
motif within the microenvironment of the liver metastasis. For
an initial molecular analysis, we selected a panel of peptides
(n¼ 7) derived from screenings with the CX7C library:
CLRSGRGSC, CLRPGLRSC, CGIYRLRSC, CMRYALRSC,
CARPGLRSC, CLRSGSGSC and CGVYSLRSC. We first evaluated
binding of the corresponding phage clones to human cell lines
from different primary tumours and metastases (n¼ 12). All
these phages showed binding preference for NCI-H630 cells
(liver metastasis from CRC), with CGIYRLRSC and CGVYSLRSC
as the most specific ligands (Fig 1B). We next evaluated phage
binding to cells freshly extracted from patients (n¼ 5) and found
that most clones recognized liver metastases with high
selectivity (Fig 1C). Specific binding was higher on primary
cells (range, 2.8–50.2) compared to the NCI-H630 cell line
(range, 1.6–10.3), a result indicating that cell types other than
epithelial cells might be targeted and/or that in fresh human
tissues the targets are more accessible than in the corresponding
cell lines. To investigate the tissue distribution of potential
targets, we performed binding overlay assays on a panel of
different human epithelial tumour types and their correspond-
ing metastases (n¼ 31). Consistently, CGIYRLRSC-phage iden-
tified 80% of the liver metastases from CRCs, with barely
detectable staining of other tissue types (Fig 1D). Notably, cellEMBO Mol Med (2012) 4, 1–20
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Figure 1. Phage display-selected peptides as ligands for human liver metastasis from CRC.
A. Three phage displayed-peptide libraries were screened on sample pairs from 22 patients, by preadsorption on control tissues (grossly normal liver) followed
by enrichment on target tissues (hepatic metastasis). In 13 experiments, a selective enrichment in phage binding was observed. Sequencing of the derived
265 phage inserts revealed 203 unique metastasis-binding peptide sequences; of these, 23% shared the LRS tripeptide motif.
B–E. CLRSGRGSC-, CLRPGLRSC-, CGIYRLRSC-, CMRYALRSC-, CARPGLRSC-, CLRSGSGSC- or CGVYSLRSC-phage was incubated with the indicated cell lines (B, in
black: primary tumour; in red: hepatic metastasis; in green: metastasis in other sites) or with suspended cells of human liver metastasis from five patients (C)
Numbers were normalized first to the degree of binding to the insertless fd-tet phage and subsequently to that of normal liver cells. Results are shown as
mean standard deviation for each experimental point in five independent experiments. Statistical significance was evaluated by ANOVA followed by
Bonferroni’s post-test, keeping as a reference a 1.5-fold threshold assumed as positive phage binding. For phage overlay assays, 10-mm cryostatic tissue
sections were incubated with 108 TU of either fd-tet or CGIYRLRSC-phage (D). A representative assay is shown. The insertless fd-tet phage was used as a
negative control; blood vessels were stained with anti-CD31 antibody, arrowheads point to the same vessels in consecutive sections (E). Asterisks indicate
the following p-value ranges: p<0.05, p<0.01, p< 0.001.
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4clusters in close proximity to blood vessels were generally well
targeted by the CGIYRLRSC-phage (Fig 1E). In these same
assays, the CGVYSLRSC-phage showed similar staining (data
not shown).
Angiopoietin-like 6 mimics two metastasis-binding peptides
and is enriched in hepatic blood vessels of patients with
metastatic CRC
Because the biopanning experiments were performed on a
mixture of intact cells and tissue stroma, the selected peptides
represent prototype ligands for the extracellular microenviron-
ment of liver metastases. To identify natural ligands mimicked
by these peptides, we focused a BLAST query on proteins similar
to the closely related peptide inserts GIYRLRS and GVYSLRS.
Among the soluble factors identified (Supporting Information
Table S1), angiopoietin-like 6 is of particular interest, because it
shares similarity with these peptides in two regions of its
fibrinogen-like domain. Interestingly, angiopoietin-like 6 mRNA
has been detected exclusively in the liver in humans (Kim et al,
2000). To investigate whether angiopoietin-like 6 could actually
act as a ligand for the hepatic homing of metastatic CRC cells, we
first evaluated the presence of this protein in several tissue types
from healthy donors. We confirmed that normal hepatic tissues
produce the highest amounts of angiopoietin-like 6, although its
expression was detectable in most tissues, a result possibly
related to the improved sensitivity of our staining protocol
compared to the whole tissue mRNA analysis of Kim et al.
Remarkably, the lung, another common site of CRC metastasis,Figure 2. Angiopoietin-like 6 is highly expressed in hepatic tissues in human
A–L. Paraffin-embedded normal tissue samples from healthy donors were cut in
antibody. (A) pancreas, (B) breast, (C) cerebellum, (D) stomach, (E) liver, (F) i
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.was one of the tissues with the highest angiopoietin-like 6 levels
(Fig 2).
We next asked whether angiopoietin-like 6 was differentially
expressed in grossly normal livers from metastatic CRC patients
(n¼ 79) in comparison to livers from healthy donors (n¼ 17;
Supporting Information Fig S1). Although the overall staining
for angiopoietin-like 6 in hepatocytes was similar, this ligand
significantly accumulated in hepatic blood vessels of cancer
patients in comparison to those of healthy individuals (Fig 3A).
A closer histological evaluation of normal liver samples from
patients with metastatic CRC revealed that angiopoietin-like 6 is
present in large blood vessels as well as in capillaries, sinusoids
and lymphatics, all potential sites for the molecular recognition
of circulating CRC cells through specific ligand/receptor
interactions (Fig 3B).
Alpha 6 integrin and E-cadherin are receptors for an
angiopoietin-like 6-mimicking peptide and participate
in a supramolecular complex in human liver metastasis
secondary to CRC
We produced soluble CGIYRLRSC as a fusion peptide
with glutathione S-transferase (CGIYRLRSC-GST) to exploit its
interaction with NCI-H630 cell surfaces (Fig 1B) towards
the identification of potential receptors. HepG2 cells, which
do not bind the CGIYRLRSC-phage (Fig 1B), served as a negative
control. We incubated CGIYRLRSC-GST with both cell
lysates, followed by separation of the bound proteins by
sodium dodecyl sulfate–polyacrylamide gel electrophoresiss.
5-mm sections and stained with the rabbit polyclonal anti-angiopoietin-like 6
ntestine, (G) oesophagus, (H) lung, (I) bladder, (J) spleen, (K) kidney, (L) testis.
EMBO Mol Med (2012) 4, 1–20
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Figure 3. Angiopoietin-like 6 is enriched in hepatic vessels of patientswithmetastatic CRC, and a6 integrin and E-cadherin are part of amolecular complex
in liver metastases from CRC.
A,B. The localization of angiopoietin-like 6 was evaluated on 5-mm sections of paraffin-embedded normal livers from 17 healthy donors and grossly normal livers
from 79 CRC patients. Two independent pathologists assigned an intensity score for angiopoietin-like 6 staining in blood vessels, and the differences
between sample categories were evaluated by a Chi-squared test (A). Exemplary pictures of two grossly normal liver samples from patients with metastatic
CRC immunostained for angiopoietin-like 6 are shown (B).
C. NCI-H630 and HepG2 were cultured on glass slides for 24 h, followed by immunostaining for E-cadherin and a6 integrin. The interaction between these
proteins was confirmed by co-IP: 10mg of total NCI-H630 protein was subjected to IP with anti-E-cadherin or anti-a6 integrin antibody, and proteins were
separated by 10% SDS–PAGE. Blotted PVDF membranes were exposed to anti-a6 integrin or anti-E-cadherin antibody, respectively. Proteins eluted from the
preclearing step (PC) were loaded as specificity controls. The localization of a6 integrin and E-cadherin was also evaluated on 10-mm sections of OCT-frozen
tissue pairs from CRC patients; arrowheads indicate colocalization. A representative staining of normal liver tissue is shown. The interaction between a6
integrin and E-cadherin was confirmed by co-IP: 4mg of total protein from five pooled samples of grossly normal liver and liver metastases was subjected to
IP with anti-E-cadherin antibody, and proteins were separated by 10% SDS–PAGE. The blotted PVDF membrane was incubated with anti-a6 integrin
antibody.
D. The interaction between a6 integrin and E-cadherin was evaluated by SPR analysis. Sensorgrams report the binding of a6 integrin (100 nM) to BIAcore CM5
sensor chips coated with either E-cadherin (black line) or VEGFR2 (dotted line, control surface). The response was recorded in RU as a function of time.
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6(SDS–PAGE). Specific bands (n¼ 11) were analysed by mass
spectrometry; 37 proteins with an identification score >50 were
thereby obtained. Of this set, five cell-surface proteins (i.e.
putative receptors) and 32 cytoskeletal proteins were found, a
result indicating that a protein (or protein complex) involved in
cell adhesion and/or motility might be responsible for this
interaction. Among the cell adhesion proteins found, a6 integrin
and E-cadherin exhibited the highest identification score
(Supporting Information Table S2).
We first evaluated the localization of a6 integrin and
E-cadherin in HepG2 and NCI-H630 cells by confocal micro-
scopy. There was colocalization of these proteins in the liver
metastasis cell line NCI-H630, in which both a6 integrin and
E-cadherin were highly represented on the cell membranes. In
contrast, barely detectable immunostaining of a6 integrin and
no colocalization with E-cadherin were observed in the primary
tumour cell line HepG2. We further asked whether these
proteins could be part of a supramolecular complex in liver
metastasis cells, as indicated by mass spectrometry and by their
colocalization on the cell surface. Co-immunoprecipitation (IP)
assays confirmed that a6 integrin and E-cadherin physically
interact in NCI-H630 cells (Fig 3C). Confocal imaging analyses
performed on liver metastases from CRC patients (n¼ 6)
revealed that a6 integrin and E-cadherin were expressed by
selected groups of cells, with regions of overlap; in contrast, a6
integrin was barely detectable and the two proteins did not
colocalize in matched grossly normal livers. A co-IP assay
performed on proteins from five pooled liver metastases
confirmed the presence of an interaction between a6 integrin
and E-cadherin in these tissues; this interaction could not be
detected in samples of grossly normal liver from the same
patients (Fig 3C). These results show that a6 integrin and
E-cadherin are expressed and colocalize in regions of human
liver metastases, where they are part of a molecular complex. To
elucidate whether a6 integrin and E-cadherin interact with each
other on the outside of the cells, and to quantify their binding
affinity, we performed surface plasmon resonance (SPR)
analyses using their recombinant extracellular portions. For
this purpose, E-cadherin was immobilized on a BIAcore CM5Figure 4. Angiopoietin-like 6 interacts with a6 integrin and E-cadherin.
A. The interaction of angiopoietin-like 6 withmicrometastases was evaluated on
Endothelial cells were identified by immunostaining for CD31, and metasta
angiopoietin-like 6 and a6 integrin was performed to investigate the coloc
images of tissues from two patients are shown; arrowheads indicate coloca
B. U293 cells transduced with a6 integrin and E-cadherin weremixedwith equal
48 h, before staining for angiopoietin-like 6 and a6 integrin.
C,D. U293 cells transfected with an empty vector (mock) or with the cDNAs coding
with conditioned media from angiopoietin-like 6-secreting cells. Bound liga
intensity and expressed as percent variation compared to incubations with s
CDH1 or both mRNAs were incubated onto angiopoietin-like 6-coated microw
wild-type cells (D).
E,F. The interaction between angiopoietin-like 6 and its receptors was evaluated b
to BIAcore NTA sensor chips coated with a6b4 integrin (E), E-cadherin (F) (b
response was recorded in RU as a function of time.
G. U293 cells transducedwith a6 integrin, E-cadherin or bothwere co-cultured w
transwell membranes were fixed, stained and counted under a light microsc
deviation for each experimental point in two independent experiments. Ast
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.sensor chip; a reference chip was prepared by immobilization of
the vascular endothelial growth factor receptor 2 (VEGFR2).
These analyses confirmed that the interaction of a6 integrin with
E-cadherin is specific (Fig 3D). Although it was not possible to
perform dose–response measurements on a single sensor chip
(see Materials and Methods Section for details), repeated
injections of a6 integrin on newly prepared E-cadherin-coated
surfaces provided values of dissociation constant (Kd) ranging
from 5.3 to 16.8 nM. These results demonstrate that the
extracellular domains of a6 integrin and E-cadherin bind
directly to each other and with a relatively high affinity.
A supramolecular complex of a6 integrin and E-cadherin is
the receptor for angiopoietin-like 6
In a small subset of samples of grossly normal liver, we observed
a few cellular aggregates that were positive for the metastatic
marker phosphatase of regenerating liver 3 (PRL3; Saha et al,
2001) and for a6 integrin. Such micrometastatic foci were
associated with blood vessels, on which an extensive coloca-
lization of hepatic angiopoietin-like 6 and metastatic a6 integrin
was evident (Fig 4A).
To design a molecularly defined cell model capable of
reproducing these interactions, we prepared U293 cell clones
stably expressing (i) a6 integrin, E-cadherin or both (receptors,
metastasis side), or (ii) angiopoietin-like 6 (ligand, host tissue
side) (Supporting Information Fig 2A). In a first set of
experiments, we noticed that cells transduced with both
receptors, when mixed with cells secreting the ligand, segregate
into metastasis-like aggregates surrounded by soluble angio-
poietin-like 6 and in tight contact with angiopoietin-like
6-transduced cells (Fig 4B).
For an accurate evaluation of this ligand/receptor interaction,
we incubated a6 integrin-, E-cadherin- or a6 integrin/
E-cadherin-transduced cells with conditioned media from
angiopoietin-like 6-secreting cells, in which the protein was
detected by ELISA at a concentration ranging from 60 to
80mg/ml. Mock-transfected cells served as a reference for
background binding, and corresponding supernatants were
used as negative controls. Confocal microscopy quantification10-mm frozen sections of grossly normal liver tissues from three CRC patients.
tic cells by immunostaining for PRL3 and a6 integrin. Immunostaining for
alization of hepatic angiopoietin-like 6 and metastatic cells. Representative
lization.
amounts of cells expressing angiopoietin-like 6 and cultured on glass slides for
for the receptor proteins were grown on glass slides for 24 h before incubation
nd was revealed by fluorescence immunostaining, quantified as mean pixel
upernatants of mock-transfected cells (C). NCI-H630 cells silenced for ITGA6,
ells. Numbers of adhered cells are expressed as percent variation compared to
y SPR analysis. Sensorgrams report the binding of angiopoietin-like 6 (200 nM)
lack lines) or to the reference, nickel-saturated surfaces (dotted lines). The
ith cells expressing angiopoietin-like 6. After 48 h, cells on the lower side of the
ope at 5magnification. In C, D and G, results are shown as mean standard
erisks indicate the following p-value ranges: p< 0.01, p< 0.001.
"
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6 was capable of interacting with cells expressing either a6
integrin or E-cadherin; this interaction was strong when both
receptors were present (Fig 4C). To confirm these data, we
performed siRNA-mediated down-regulation of a6 integrin
(ITGA6), E-cadherin (CDH1) or both mRNAs (Supporting
Information Fig S3A) in NCI-H630 cells, and we evaluated theFigure 4.
EMBO Mol Med (2012) 4, 1–20 capacity of these cells to interact with angiopoietin-like 6. In this
assay, NCI-H630 cells in which both ITGA6 and CDH1 mRNAs
were down-modulated exhibited impaired adherence to micro-
wells coated with recombinant angiopoietin-like 6 (Fig 4D).
These results suggest that hepatic angiopoietin-like 6 represents
a potential, thus far unrecognized ligand for metastatic cells that
express both a6 integrin and E-cadherin. To investigate these2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 7
Research Article www.embomolmed.org
A novel ligand/receptor pair in hepatic metastasis
8interactions in detail, we again performed SPR analyses using all
recombinant proteins. Taking advantage of their his-tag, the
extracellular portions of E-cadherin and a6 integrin were
properly oriented and immobilized on nickel-activated BIAcore
NTA sensor chips. A chip saturated with nickel was used as a
reference. These analyses demonstrated that angiopoietin-like 6
binds specifically to both receptors (Fig 4E–F). Dose–response
measurements (data not shown) allowed calculating Kd values
for the interaction with a6 integrin and E-cadherin equal to 2.03
and 29.0 nM, respectively.
Angiopoietin-like 6 is a secreted factor with chemotactic
activity on endothelial cells (Oike et al, 2004). We asked
whether this ligand could also affect the motility of cells
expressing a6 integrin and E-cadherin. U293 cells transduced
with a6 integrin, E-cadherin or both were co-cultured with
angiopoietin-like 6-secreting cells in a transwell system, and
their migration towards the ligand gradient was evaluated. Co-
cultures with mock-transfected U293 cells were used as a
reference for basal cell motility. Although the presence of either
a6 integrin or E-cadherin slightly increased the migration of
U293 cells under basal conditions, this feature was not
influenced by angiopoietin-like 6. In contrast, U293 cells
expressing both a6 integrin and E-cadherin showed a basal
migratory phenotype that was stimulated significantly by
angiopoietin-like 6 (Fig 4G). These data demonstrate that the
presence of both a6 integrin and E-cadherin is necessary to
respond to a gradient of angiopoietin-like 6, further confirming a
functional role for this ligand/receptor system.
CRC cell adhesion to the hepatic tissue in vitro and liver
colonization in vivo are mediated by a6 integrin and
E-cadherin and are inhibited by an angiopoietin-like
6-mimicking peptide
To evaluate a potential role for the described system in the
process of liver metastasis, we first compared the capacity of
HepG2 and NCI-H630 cells to adhere to grossly normal livers
from CRC patients (a characterization of these cell lines in terms
of CGIYRLRSC-phage binding and of a6 integrin/E-cadherin
expression and coexpression is reported in Fig 1B and Fig 3C,
respectively). Cells were incubated on human liver sections for
increasing periods of time, ranging from 30 min to 5 days. At all
time points, HepG2 cells adhered weakly to the liver and grew in
separate aggregates. In contrast, the adhesion of NCI-H630 cells
was significantly higher; moreover, these cells could grow and
integrate into the hepatic tissue (Fig 5A), with a morphology
reminiscent of the metastasis model described in Fig 4A.
This effect was modulated by a6 integrin and E-cadherin, as
confirmed by the fact that cells in which ITGA6, CDH1 or both
mRNAs were down-modulated exhibited impaired adherence
to normal liver, with the double-silenced cells showing the
slowest adhesion (Fig 5B).
Because the insert in the CGIYRLRSC sequence mimics a
liver-enriched ligand for a6 integrin and E-cadherin, we
investigated whether the corresponding peptide could interfere
with this interaction, and thereby inhibit the adhesion of
metastatic cells to the hepatic tissue. When NCI-H630 cells were
incubated on grossly normal liver sections from CRC patients 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.(n¼ 27), there was a significant decrease in cell adhesion upon
treatment with a soluble CGIYRLRSC peptide (Fig 5C). We also
investigated the adherence to grossly normal liver of U293 cells
stably transduced with cDNAs encoding for a6 integrin,
E-cadherin or both (Fig 5D). U293 cells in which a6 integrin
was expressed, either alone or in combination with E-cadherin,
showed an increased affinity for the hepatic tissue; liver
adhesion was the most pronounced in cells expressing both
components of the receptor complex. Notably, CGIYRLRSC
inhibited adhesion of U293 cells only when they expressed both
a6 integrin and E-cadherin. We finally evaluated the adhesive
properties of different cell lines of primary CRC with proven
in vivo metastatic behaviour, e.g. HCT-116m, HT-29 (Price et al,
1989), SW-48 and DLD-1 (Tibbetts et al, 1993; Fig 5E,
Supporting Information Fig 2B). These cells exhibited remark-
able adhesion to grossly normal liver, which was significantly
inhibited by CGIYRLRSC. The non-metastatic version of HCT-
116 cells, which express very low levels of the receptor proteins,
adhered poorly to the hepatic tissues and was not affected by
CGIYRLRSC. These results suggest that CGIYRLRSC-mimicking
proteins, such as angiopoietin-like 6, can act as microenviron-
ment addresses for metastatic cells that express a6 integrin and
E-cadherin.
The data obtained in vitro prompted us to ask whether similar
mechanisms would be involved in hepatic colonization in vivo.
To study the metastasis/host tissue interaction, we established
an animal model of hepatic colonization by direct injection of
human CRC cell lines into the livers of CD-1 nude mice. For a
molecular analysis of the receptor side, we achieved stable
shRNA-mediated silencing of ITGA6 or CDH1 mRNA in different
cell lines of primary CRC, e.g. HCT-116m, HT-29, SW-48 and
DLD-1 (Supporting Information Fig S3B). All the cells in which
either component of the receptor complex was silenced
exhibited an impaired capability to form tumours after injection
into the liver; this effect reached statistical significance in SW-48
and HT-29 cells in which a6 integrin was silenced, and in HCT-
116m, SW-48 and DLD-1 cells in which E-cadherin was silenced.
By confocal microscopy we confirmed that the decreases in
specific proteins were retained in vivo, with an almost complete
disappearance of coexpressed a6 integrin and E-cadherin from
the tumour tissues (Fig 6). These data show that even an
incomplete depletion of only a receptor protein is sufficient to
alter liver colonization by CRC cells.
We next evaluated whether interference with the described
ligand/receptor pair would lead to impaired hepatic coloniza-
tion. For this set of experiments we used LS-174T, a cell line
derived from a primary CRC that exhibits high expression of
the complex proteins (Supporting Information Fig 2B) and an
aggressive behaviour in vivo (Tibbetts et al, 1993). We injected
animals with LS-174T cells either in medium alone or in the
presence of CGIYRLRSC. After 14 days we explanted the livers
for tumour quantification. We observed a significant reduction
of liver tumours in mice injected with LS-174T cells in the
presence of the angiopoietin-like 6-mimicking peptide, although
the overall morphology and the levels of a6 integrin and
E-cadherin, as well as their colocalization, were unchanged
(Fig 7A). These results indicate that CGIYRLRSC mightEMBO Mol Med (2012) 4, 1–20
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Figure 5. Alpha 6 integrin/E-cadherin-mediated liver adhesion is counteracted by an angiopoietin-like 6-mimicking peptide.
A,B. HepG2 and NCI-H630 were incubated on 10-mm frozen sections of grossly normal liver from CRC patients, and adhered cells were fixed, haematoxilin-
stained and counted under a light microscope at 20magnification. Photomicrographs representative of cell numbers (120min) and morphology (5 days)
are shown. The dotted line indicates amicrometastasis-like structure integrated into the liver tissue; arrowheads point to cell aggregates (A). NCI-H630 cells
silenced for ITGA6, CDH1 or bothmRNAs were challenged in the same assay (B). Results are shown as mean standard deviation for each experimental point
in three independent experiments.
C–E. NCI-H630 cells (C), U293 cells transduced with a6 integrin, E-cadherin or both (D) and CRC cell lines (E) were incubated with 10-mm frozen sections of
grossly normal liver in the presence of either control or CGIYRLRSC peptide. After 30min, adhered cells were fixed, stained and counted under a light
microscope at 5 magnification. For NCI-H630 cells, adhesion was evaluated on sections from 27 patients and results are shown as the ratio of attached
cells comparing CGIYRLRSC and control peptide incubations. In A, B, D and E, differences in the experimental points were evaluated for their statistical
significance by ANOVA followed by Bonferroni’s post-test. In C, a Chi-squared test was used to evaluate whether values were significantly different from 1.interfere with early steps of tumour/host tissue recognition,
without influencing successive tumour growth. Consistently,
CGIYRLRSC has no effects on the proliferation of U293 cells
transduced with a6 integrin, E-cadherin or a combination of
both receptors (Fig 7B).
An angiopoietin-like 6-mimicking peptide has antimetastatic
effects in preclinical models of human CRC
Having demonstrated that in vitro angiopoietin-like 6 is a potent
chemoattractant for cells expressing a6 integrin and E-cadherin
(Fig 4F), we asked whether the angiopoietin-like 6-mimicking
peptide CGIYRLRSC could interfere with the homing of CRC cells
to the liver in vivo. To obtain a pseudo-orthotopic preclinical
model of metastatic CRC, we implanted the human tumour
HCCM-1544 (Giavazzi et al, 1986), as well as a panel of human
cell lines (HCT-116m, SW-48, DLD-1 and LS-174T) into the
spleens of CD-1 nude mice. Cells were injected either in medium
alone or in the presence of CGIYRLRSC. Mice were euthanized atEMBO Mol Med (2012) 4, 1–20 different time points after cell injection, from 20 (HCT-116m) to
195 days (DLD-1), reflecting the different aggressiveness of the
cell lines. At the time of sacrifice, in all the tumour models a
primary splenic mass and a variable number of liver metastases
were present; the frequency of hepatic involvement in the
vehicle group varied from 11% (DLD-1) to 100% (LS-174T).
Treatment with CGIYRLRSC resulted in diminished homing of
CRC cells to the liver, and was significant in all the models
investigated, with the exclusion of the poorly metastatic DLD-1
cell line (Fig 8). These data confirm that CGIYRLRSC inhibits
liver homing of CRC cells independently of the characteristic
features (timing, size and number of metastases) of each model.
In all the experimental settings, we observed a substantial
increase in both a6 integrin and E-cadherin, with diffuse regions
of colocalization, in liver metastases as compared to primary
spleen tumours (Fig 8). This result suggests that the expression
of such proteins is augmented and/or that highly expressing
cells are selected during metastatic progression.2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 9
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Figure 6. Impaired expression of a6 integrin or E-cadherin results in impaired liver colonization in vivo. HCT-116m, SW-48, DLD-1 and HT-29 cell lines with
down-modulated expression of a6 integrin or E-cadherin were injected intrahepatically into CD-1 nude mice (6–10mice/group, 5 106 cells/mouse). At the
indicated time points, mice were euthanized, and their livers were explanted and photographed for the quantification of external tumour areas. Representative
pictures of whole livers from 2mice/group are shown for macroscopic evaluation of tumour morphology; the indicated p-values are referred to statistical analysis
performed with Fisher’s exact test (black) or t-test (red). Sample tissues were OCT-frozen, cut in 10-mm sections, and immunostained with anti-a6 integrin and
anti-E-cadherin antibodies, followed by imaging with a confocal microscope. Acquisition parameters were held constant to allow comparison of the absolute
amounts and localizations of a6 integrin and E-cadherin among the different samples. Exemplary pictures of samples from 1mouse/group are shown.
10The levels of a6 integrin/E-cadherin coexpression correlate
with the progression of human metastatic CRCs
We finally evaluated the role of the described ligand/receptor
system from a clinical perspective. By quantitative confocal
imaging, we evaluated the amounts of a6 integrin, E-cadherin
and their colocalization in the following tumour settings:
primary CRCs (Duke’s stage IV; n¼ 22; Fig 9A), liver metastases 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.from CRC (n¼ 100; Fig 9B), liver metastases from other cancers
(n¼ 22; Fig 9C), and lung metastases from CRCs (n¼ 40;
Fig 9D). This analysis revealed that the presence of the a6
integrin/E-cadherin complex is constant in advanced CRCs,
from primary adenocarcinomas to liver and lung metastases.
Conversely, liver metastases from different primary tumours
exhibited variable expression of a6 integrin and E-cadherin,EMBO Mol Med (2012) 4, 1–20
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Figure 7. An angiopoietin-like 6-mimicking peptide interferes with liver colonization but not with the proliferation of human metastatic CRC cells.
A. CGIYRLRSC interferes with hepatic colonization in vivo. LS-174T cells were injected intrahepatically into CD-1 nude mice (6mice/group, 5 106 cells/mouse),
either in medium alone (vehicle) or in the presence of CGIYRLRSC. Fourteen days after surgery, animals were euthanized and tissues were processed as
described in Fig 6. The indicated p-value is referred to statistical analysis performed with Fisher’s exact test.
B. U293 cells expressing E-cadherin, a6 integrin or both were grown in complete culture medium, in the presence of either control or CGIYRLRSC peptide. At 24 h
time points, cells were fixed and stained with crystal violet; their numbers were estimated by spectrophotometric evaluation. Results are shown as
mean standard deviation for each experimental point in three independent experiments.which resulted in their colocalization in <50% of the samples
examined. A correlation analysis with the clinical outcome of
CRC patients revealed that high levels of a6 integrin, E-cadherin,
and their coexpression in liver metastases were all associated
with shorter disease-free survival after surgical intervention
(Fig 10). In primary adenocarcinomas, despite an inverse
correlation with the levels of E-cadherin and lack of correlation
with respect to a6 integrin, high amounts of colocalized a6
integrin and E-cadherin were nevertheless associated with
shorter disease-free survival (Fig 10). These data indicate that
the amounts of coexpressed a6 integrin/E-cadherin might be
exploited as a new prognostic factor to identify a subset of
metastatic CRCs characterized by fast disease progression.DISCUSSION
Understanding the early steps of metastasis is crucial from
a therapeutic perspective, because at this stage specificEMBO Mol Med (2012) 4, 1–20 molecular mechanisms likely define the metastatic destination
of cancer cells, and therefore targeted inhibitors could make
the difference in a patient’s prognosis. Although studies have
been ongoing since Paget first proposed the ‘‘seed and soil’’
hypothesis (Paget, 1889), many questions remain. For breast
cancer, a match between tumour-expressed receptors and host
tissue-expressed chemokines appears to be the driving force for
the onset of metastasis. In this pathological context, specific
signalling pathways have recently emerged that are selectively
involved in lung (Minn et al, 2005) or brain (Bos et al, 2009)
metastasis. For CRC, with the exception of the specific liver
colonization of metastatic cells (Kuo et al, 1995) and site-
dependent variations in therapeutic responses (Dong et al,
1994), little is known about the mechanisms that drive hepatic
homing and colonization. Indeed, current therapies for
advanced CRC target molecules that are related to cancer
progression [e.g. VEGF (Grothey & Galanis, 2009) and EGFR
(Okamoto, 2009)], rather than counteract the initiation of
metastasis.2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 11
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Figure 8. An angiopoietin-like 6-mimicking peptide inhibits homing of CRC cells to the liver. To obtain an in vivo pseudo-orthotopic model of metastatic CRC,
we implanted the human tumour HCCM-1544, and the cell lines HCT-116m, SW-48, DLD-1 and LS-174T, intrasplenically into CD-1 nude mice (6–10mice/group,
2 106/mouse). Cells were injected in medium alone (vehicle) or in the presence of CGYIRLRSC. At the indicated time points, mice were euthanized, and tissues
were processed as described in Fig 6.
12The difficulty in addressing the metastatic process resides in
the high variability of cancer cells, a consequence of several
events that occur in the life history of a tumour. Different
hypotheses have been debated for decades that focus on at least
two mechanisms providing valuable models for metastasis
progression. The first is the selection and expansion of
metastatic clones preexisting in the primary tumour (Talmadge,
2007), which was demonstrated in mouse models (Fidler &
Kripke, 1977) and subsequently confirmed in patients
(Klein et al, 2002). The second is adaptation of cancer cells
to signals from recruited (normal) stromal cells (Condeelis &
Pollard, 2006; Scheel et al, 2007). Adaptation mechanisms
have been observed both in primary tumours, in which
malignant cells exploit contextual signals to undergo the 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.epithelial–mesenchymal transition (Thiery & Sleeman, 2006),
as well as in distant metastases, where the opposite transition
may occur (Chaffer et al, 2006). In some cases, adaptation is
made easier: some microenvironments show an intrinsic or
preinduced permissiveness for colonization by circulating
cancer cells (Coghlin & Murray, 2010; Peinado et al, 2011;
Talmadge, 2010). It is now clear that composite events are
exploited by cancer cells for their malignant progression, and
that Darwinian selection of genetic/epigenetic variants is
complemented by opportunistic adaptation to the host physio-
logy (Hanahan & Weinberg, 2011). In this view, a system of
tumour/host attraction and colonization will be greatly
favoured, provided that it meets at least one of the following
requirements.EMBO Mol Med (2012) 4, 1–20
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Figure 9. a6 Integrin, E-cadherin and their molecular complex are associated to advanced CRCs.
A–D. The presence of a6 integrin and E-cadherin was evaluated by immunostaining of 5-mm sections of a panel of paraffin-embedded cancer tissues (A, primary
CRCs; B, Liver metastases from CRCs; C, liver metastases from other primary tumours, the origin of which is indicated in the table; and D, lung metastases
from CRCs). The quantification of specific fluorescent signals is described in the Material and Methods Section.The first one is profiting by preexisting components. Here we
describe a molecular mechanism for liver metastasis that is
based on a liver-enriched, naturally occurring ligand, angio-
poietin-like 6 and on receptors already present in primary CRCs,
a6 integrin and E-cadherin. As proof of this aspect of the
adaptation hypothesis, the accumulation of angiopoietin-like 6
in liver vessels is significantly increased in patients with
metastatic CRC in comparison to healthy individuals. Vessel-
enriched angiopoietin-like 6 might be secreted by (primary or
metastatic) tumour cells; alternatively, it might be induced inEMBO Mol Med (2012) 4, 1–20 normal liver cells by tumour-derived factors. The consequent
increase in docking sites for circulating CRC cells can be further
accompanied by the onset of autocrine circuits in malignant cells
themselves. Furthermore, we demonstrate that (i) subsets of
cells characterized by high levels of coexpressed a6 integrin and
E-cadherin are enriched during the progression from primary
tumour to hepatic metastasis in animal models, and (ii) patients
whose primary adenocarcinomas express high amounts of
this receptor exhibit a shorter disease-free survival. Although
more extensive investigation is needed to elucidate the2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 13
Research Article www.embomolmed.org
A novel ligand/receptor pair in hepatic metastasis
Figure 10. The coexpression of a6 integrin and E-cadherin is a poor prognostic factor for patients with metastatic CRC. The amounts of a6 integrin,
E-cadherin, and their molecular complex in primary CRCs (grade IV) and liver metastases from CRCs were correlated with disease-free survival. Survival curves
were drawn as Kaplan–Maier Cumulative Proportion Surviving graphs and corresponding p-values were calculated by the use of the log-rank (Mantel-Cox) test
with Prism 5 GraphPad software.
14physiopathological mechanisms, these data are reminiscent of
the pro-metastatic systemic perturbation described by Weinberg
and coworkers (McAllister & Weinberg, 2010).
The second requirement relates to the adaptability of protein–
protein interactions. In addition to mutation and/or amplifica-
tion of oncogenic molecules, a driving mechanism in cancer
progression appears to be the emergence of unusual protein
partners whose association results in altered biological
activities. For example, E-cadherin has been shown to interact
directly with aEb7 integrin to mediate heterotypic adhesion
between T-lymphocytes and epithelial cells under physiological
(Cepek et al, 1994) and pathological (Le Floc’h et al, 2007)
conditions. In a CRC cell line, E-cadherin interacts with insulin-
like growth factor-I receptor and av integrin; upon ligand
stimulation, this complex is destroyed and the integrin is
relocalized from intercellular contacts to focal adhesions, a
condition leading to increased cell motility (Canonici et al, 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.2008). We show for the first time that a heretofore unrecognized
complex of E-cadherin and a6 integrin is present on the surface
of CRC cells, with a functional role in liver homing and
colonization. This mechanism could be exploited by other
tumours that metastasize to the liver, as suggested by the
presence of this complex in 50% of the non-CRC liver
metastases that we have investigated.
A third requirement exploits modular interactomes.
Degenerate patterns of protein–protein recognition can build
up dynamic networks. As an example, RGD is a recognition
motif shared by several integrin substrates, whose flanking
regions confer affinity for receptor binding (Humphries et al,
2006). Such a system opens a plethora of possibilities for a
parasite cell to find potential molecular partners in a host
microenvironment; it is therefore not surprising that our
biopanning experiments resulted in the enrichment of con-
served peptide motifs as ligands for metastatic CRC cells.EMBO Mol Med (2012) 4, 1–20
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proteins share similarity with the metastasis-specific peptides,
among which a proteoglycan (perlecan) and a component of the
basal lamina (laminin a2), both involved in angiogenesis and
cancer progression (Theocharis et al, 2010; Vitolo et al, 2006). A
further ligand emerging from this search was osteopontin, a
secreted phosphoprotein with a recognized role in metastatic
CRC. Interestingly, in the primary sequence of osteopontin, the
LRS motif is only five amino acids beyond the RGD domain. The
region starting with LRS is proteolytically cleaved by metallo-
proteinase-9, to release a fragment in which a cryptic adhesive
sequence is revealed that exhibits altered affinity for integrins
and acquires pro-metastatic activity (Green et al, 2001; Smith
et al, 1996; Takafuji et al, 2007).
Taken together, these observations strengthen our suggestion
that the angiopoietin-like 6/a6 integrin/E-cadherin system is
part of an interconnected network, in which several proteins
interact with different molecular partners based on their
availability, combination and affinity. It is possible that a
targeted approach mediated by CGIYRLRSC or other metastasis-
binding peptides might interfere with a number of protein–
protein interactions based on this pattern recognition, thereby
resulting in an amplification of the therapeutic outcome. The
fact that extracellular proteins share common features has
complicated the elucidation of their interactions with the single-
molecule approaches used in the recent past. Conversely, we
demonstrate that combinatorial profiling can lead to the
identification of functional addresses as putative molecular
targets within the microenvironment of human hepatic
metastasis (Marchio` et al, 2009). In this case, the presence of
overlapping protein motifs will facilitate targeting the metastatic
site even without specific knowledge of each participant.MATERIALS AND METHODS
Antibodies, proteins, peptides
Goat polyclonal anti-a6 integrin N-19 (for immunoblot) and anti-
vinculin N-19, rabbit polyclonal anti-b4 integrin H-101 (for ELISA)
(sc-9090) and horseradish peroxidase (HRP)-conjugated anti-goat IgG
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse
monoclonal anti-a6 integrin clone BQ16 (used for IP) was obtained
from Calbiochem (San Diego, CA). Rat monoclonal anti-a6 integrin
clone GoH3 (for immunostaining) was obtained from AbD Serotec
(Raleigh, NC). Mouse monoclonal anti-b4 integrin clone 7 (for
immunoblot) and anti-E-cadherin clone 36 were obtained from BD
Transduction Laboratories (Franklin Lakes, NJ). Rabbit polyclonal anti-
fd bacteriophage was obtained from Sigma (St. Louis, MO). Alexa
Fluor1488 anti-rat and 555 anti-mouse IgG were obtained from
Invitrogen (Carlsbad, CA). HRP-conjugated anti-mouse IgG was
obtained from Jackson ImmunoResearch (West Grove, PA). Mouse
monoclonal anti-CD31 clone JC70A and HRP-conjugated anti-rabbit
EnVision were obtained from DAKO (Glostrup, Denmark). Rabbit
polyclonal (for immunostaining) and mouse monoclonal clone
Kairos-60 (for immunoblot) anti-angiopoietin-like 6, and angiopoie-
tin-like 6 were obtained from Alexis Biochemicals (Enzo Life
Sciences, Farmingdale, NY). Rabbit polyclonal anti-PRL3 was a giftEMBO Mol Med (2012) 4, 1–20 of Dr. Alberto Bardelli (IRCC; Bardelli et al, 2003). CGIYRLRSC
and control (CARAC) peptides were obtained from New England
Peptides (Gardner, MA). Recombinant Fc-his-tag-E-cadherin,
his-tag-a6b4 integrin, and Fc-his-tag-VEGFR2 (all extracellular
portions) were obtained from R&D Systems (Space Import-Export,
Milan, Italy).
Cell lines and human samples
SW480, SW620, NCI-H630, HepG2, AGS, NCI-N87, Capan-2), Capan-
1, BT-474, MCF-7, A549, NCI-H1688, HCT-116, HT-29, DLD-1, SW-48,
LS-174T and U293 cells were obtained from LGC-Promochem (Sesto
San Giovanni, Italy), and were cultured according to the provider’s
instructions. The HCCM-1544 human metastatic CRC has been
previously described (Giavazzi et al, 1986). A variant of HCT-116,
selected in vivo for its capacity to metastasize to the liver in pseudo-
orthotopic models (HCT-116m), was provided by Dr. Alberto Bardelli.
Fresh (grossly normal liver from CRC patients, primary CRC, liver
metastasis from CRC), and paraffin-embedded human specimens
(grossly normal liver from CRC patients, primary CRC, liver metastasis
of various origins) were collected by the Units of Surgical Oncology
and Pathology at the IRCC and Mauriziano Hospital (Torino, Italy).
Paraffin-embedded human specimens of normal liver from healthy
donors, of lung metastasis from CRC, and of different healthy
tissues were collected by the Unit of Pathology at Molinette Hospital
(Turin, Italy). Snap-frozen samples of lung metastasis from CRC and
of liver metastasis from renal cancer were obtained from San
Luigi Gonzaga Hospital (Orbassano, Italy); snap-frozen samples of
ovarian cancer and sigma metastasis were obtained from Mario
Negri Institute (Milan, Italy). Collection and manipulation of human
samples were approved by the Institutes’ Ethical Committees;
informed consent was obtained in accordance with the Declaration
of Helsinki.
Phage display
Tissue samples were digested with 0.025% collagenase A (Roche
Diagnostics, Monza, Italy) in Iscove’s Modified Dulbecco’s Minimum
Essential Medium (IMDM) for 2 h at 378C. The resulting suspension
was passed through a 40mm nylon cell strainer (BD Labware, Franklin
Lakes, NJ), and cells were resuspended and maintained in binding
medium (IMDM supplemented with 2% foetal calf serum, FCS) at 48C
for the duration of the experiments. 1010 transducing units (TU) of a
CX7C, CX9C or CX3CX3CX3C phage library was added to 5105 liver
metastasis cells and incubated overnight (first round). For successive
rounds, phage was preadsorbed on grossly normal liver cells for 1 h
at 48C and then incubated with liver metastasis cells for 2 h at 48C.
Cells were washed five times in binding medium, and bound phage
was recovered and amplified by infection of K91Kan Escherchia coli
bacteria in log-phase. Purification of phage particles and DNA
sequencing of phage-displayed inserts were performed as described
(Scott & Smith, 1990; Smith & Scott, 1993). Binding on whole cells
was performed with 109 TU of each phage on 5105 suspended cells
in binding medium as described (Marchio` et al, 2004). For overlay
experiments, 5109 TU/ml of each phage was incubated with 10-mm
sections of OCT-frozen tissues and detected as described (Arap et al,
2002), with the EnVision system (DAKO) and 3-amino-9-ethylcarb-
azole (AEC) as substrate. Images were acquired with an EC3 Leica
camera (Leica Microsystems, Milan, Italy).2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 15
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16Identification of peptide-targeted proteins
The following oligonucleotides were annealed and inserted into
pGEX-4T.1 between BamHI and NotI sites to create the pGEX-4T.1-
CGIYRLRSC plasmid:
50-GATCCGGAGCCTGTGGAATATATAGATTAAGAAGTTGTGCGGGCGC-30 and
50-GGCCGCGCCCGCACAACTTCTTAATCTATATATTCCACAGGCTCCG-30 .
The corresponding fusion peptide was purified from BL-21 E. coli cell
lysates by affinity chromatography on glutathione-sepharose beads
(GE Healthcare, Chalfont St. Giles, UK), according to the manufacturer’s
protocol. HepG2 and NCI-H630 cells were lysed in 50mM Tris–HCl
(pH 7.4), 150mM NaCl, 0.1% NP-40, 10% glycerol and a protease
inhibitor cocktail (Sigma). Ten milligrams of total protein was pre-
cleared on GST-Sepharose (GE Healthcare) prior to incubation with
CGIYRLRSC-GST-Sepharose (4mg peptide/mg total protein) overnight
at 48C. Bound proteins were eluted from Sepharose beads, separated
on a 10% SDS–polyacrylamide gel, and stained with BioSafe
Coomassie blue (BioRad, Hercules, CA). Specific bands were analysed
by mass spectrometry: matrix-assisted laser desorption/ionization
(MALDI) mass spectra were recorded on an Applied Biosystems
Voyager DE-PRO mass spectrometer equipped with a reflectron
time-of-flight (TOF) analyser and used in delayed extraction mode
(Applied Biosystems, Foster City, CA). Raw data, reported as mono-
isotopic masses, were introduced into the MASCOT peptide mass
fingerprinting search program (Matrix Science, Boston, MA) for protein
identification. Liquid chromatography (LC)-mass spectrometry (MS)/
MS analyses were performed on a CHIP MS Ion Trap XCT Ultra
equipped with a 1100 high pressure liquid chromatography (HPLC)
system and a chip cube (Agilent Technologies, Palo Alto, CA). Analysis
was performed by data-dependent acquisition of one MS scan (mass
range from 400 to 2000m/z) followed by MS/MS scans of the three
most abundant ions in each MS scan. Raw data from nanoLC-MS/MS
analyses were introduced into the MASCOT software to search the
human proteome.
Preparation of stably transduced U293 cells
FLAG-tagged human angiopoietin-like 6 cDNA, inserted into
pcDNA3.1(þ).Neo vector (pcDNA3.ANGL6), was a gift from Dr. Y. Oike
(Japan Science and Technology Agency, Japan; Oike et al, 2005);
human E-cadherin cDNA, cloned into pcDNA3.1(þ).Neo vector
(pcDNA3.CAD1) was a gift from Dr. C. Gottardi (North Western
University Medical School, Chicago, IL; Gottardi et al, 2001); b4
integrin cDNA, cloned into PRK5 plasmid (pRK5.ITB4), was purchased
from Addgene (Cambridge, MA); human a6A integrin cDNA, inserted
into pLXSN plasmid (pLa6SN; Tamura et al, 1990), was a gift from Dr.
A. Magrelli (La Sapienza University, Rome, Italy). The latter cDNA insert
was PCR-amplified with the following primer pair:50-AAACTTAAGCTTGCCACCATGGCCGCCGCCGGGCAG-30 and
50-TACACGGGCCCTCTATGCATCAGAAGTAAGCCT-30and subcloned into pcDNA3.1(þ). Hygro vector between HindIII and
ApaI sites to obtain the pcDNA3.ITA6A plasmid. To achieve correct
processing and high amounts of a6A integrin, a concomitant
expression of its molecular partner b4 integrin was necessary. For
stable overexpression of a6Ab4 (abbreviated as a6 in the text) integrin, 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.E-cadherin, and angiopoietin-like 6, U293 cells were transduced with
the described plasmids by the use of a calcium phosphate transfection
kit (Invitrogen), followed by selection of single cell clones in
culture media supplemented by 500mg/ml, geneticin (Sigma) and/or
200mg/ml hygromycin (Invitrogen). Angiopoietin-like 6 was quanti-
fied in cell supernatants by using the #96-well ANGPLT6 ELISA Kit
(Adipogen, San Diego, CA).
Preparation of cell lines with silenced expression of
target genes
A transient gene silencing approach was applied to cells used for
short-term in vitro experiments. NCI-H630 cells were transduced with
ON-TARGETplus SmartPOOL siRNA for ITGA6 and CDH1, or with control
siRNA (Dharmacon, Lafayette, CO). For each experimental point,
2105 cells were transfected with either control, ITGA6, CDH1 or
both siRNA pools, according to the manufacturer’s protocol. To
quantify gene down-modulation, we evaluated RNA and protein levels
after 24 and 72h, respectively. A stable silencing approach was
preferred for cells used for long-term, in vivo experiments. For this
purpose, 2105 HCT-116m, SW-48, HT-29 or DLD-1 cells were
transfected with shRNA plasmid pools targeting ITGA6 or CDH1, or
with non-targeting control shRNA plasmid pool A (all from Santa Cruz
Biotechnologies), according to the manufacturer’s protocol. Following
selection in medium supplemented with 2.5mg/ml puromycin (Sigma),
six clones for each experimental point were subjected to dotblot
analysis to confirm selective protein down-regulation. For this
purpose, cell lysates (1mg each) were spotted onto polyvinylidene
fluoride (PVDF) membranes; after drying, membranes were subjected
to specific antibody staining with standard procedures.
Retrotranscription and real-time PCR
RNA was retrotranscribed by the use of the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems) and amplified with the
Power SYBR Green PCR Master Mix (Applied Biosystems). For residual
transcript quantification in silenced cells, the following primer pairs
were used for real-time PCR amplification of the cDNAs in an ABI
PRISM 7700 instrument:
ITGA6: 50-TGAGTGTCCCCCGGTATCTTC-30 and 50-CAGTATCAGCCGCTTT-
CAGATTTT-30 ;
CDH1: 50-GCTGGTTATAATCCTTCAATATCAATTGT-30 and 50-TTGGGCTCA-
GAACCTTGGTTT-30 ;
GAPDH: 50-GAAGGTGAAGGTCGGAGTC-30 and 50-GAAGATGGTGATGG-
GATTTC-30 .
Immunostaining
OCT-frozen tissues were cut into 10-mm sections, and paraffin-
embedded tissues into 5-mm sections. For immunostaining of cell
lines, 104 cells were plated on a SuperFrost Plus glass slide (Menzel-
Gla¨ser, Braunschweig, Germany) and were grown for 24 h followed by
fixation in 4% paraformaldehyde in PBS for 5min at RT. Immuno-
staining was performed according to standard protocols. Visible images
were acquired with either an EC3 Leica (frozen tissues) or a High-
Performance IEEE 1394 FireWire Digital CCD Camera (QIMAGING,
Surrey, BC, Canada; paraffin-embedded tissues). Fluorescent images
were acquired with either a DMIRE2 confocal microscope or a DMIEMBO Mol Med (2012) 4, 1–20
www.embomolmed.org Research Article
Serena Marchio` et al.3000D microscope equipped with a DFC 360FX digital camera (all
from Leica). For quantification of fluorescent signal colocalizations,
three images/sample (10241024 pixels¼375375mm2) were
divided in 8-bit images corresponding to the red and green
fluorescence channels. Image pairs were analysed with the Image
Processing and Analysis software in Java (ImageJ), with the
Colocalization Highlighter plugin to create a binary representation
of colocalized pixels, and the Image Calculator option to derive the
non-colocalized pixels.
Immunoblot and IP
Cells were lysed in four pack cell volumes of phosphate-buffered saline
(PBS), 1mM CaCl2, 1mM MgCl2, 1mM PMSF, protease inhibitor
cocktail, supplemented with either 50mM b-octyl-D-glucosylpyranoside
(interaction studies) or 0.1% NP-40 (expression studies). Tissues
were homogenized in a Potter-Elvehjem grinder in the same buffer
(1ml/100mg tissue). Homogenates were cleared by centrifugation
and filtration through 0.45mm pore filters. For IP, lysates were
precleared for 1 h at 48C on Protein G-Sepharose (GE Healthcare),
followed by incubation with specific antibodies for 1 h at 48C and
addition of Protein G-Sepharose for 2h at 48C. Proteins were separated
on 10% SDS–PAGE and were blotted onto PVDF membranes (Millipore,
Billerica, MA). For protein quantification, densitometric analysis of the
detected bands was performed with QuantityOne software (BioRad);
values were normalized to the intensity of vinculin bands.
In vitro assays
To evaluate the capability of soluble angiopoietin-like 6 to bind to
adhered cells expressing a6 integrin and E-cadherin, mock- or
receptor-transduced U293 cells were plated on SuperFrost Plus glass
slides (Menzel-Gla¨ser) and were grown for 24 h. Cells were then
incubated with 100ml of conditioned media from angiopoietin-like
6-secreting or mock-transfected U293 cells for 2h at 48C, washed three
times with PBS, fixed with 4% paraformaldehyde, and stained with the
anti-angiopoietin-like 6 rabbit polyclonal antibody using standard
protocols. The intensities of fluorescent pixels were quantified in at
least 25 ROIs/sample (area¼100mm2), by using the Leica Application
Suite software, and reported as percent variation compared to the
negative controls. For investigation of cell adhesion to angiopoietin-
like 6, 1mg of the recombinant protein was incubated per well of a
96-well plate for 1 h at 378C. After a blocking step in IMDM, 2% FCS
for 1 h at 378C, 104 cells were allowed to adhere for 1 h at 378C.
Samples were washed in PBS, and cells were fixed in 8%
glutaraldehyde and stained in 0.25% crystal violet in 10% methanol.
For tissue adhesion, 10-mm sections of OCT-frozen grossly normal liver
samples from metastatic CRC patients were blocked in IMDM, 2% FCS
for 30min at 378C, followed by incubation with 5104 cells in 5%
CO2 at 378C for the indicated periods of time. Samples were washed
four times in the same medium and once in PBS, fixed in 4%
paraformaldheyde, and stained with haematoxylin (BioOptica).
Adhered cells were counted manually under a light microscope. To
test the peptide effects on cell proliferation, we plated 2104 cells
per well in a 24-well plate, in the presence of either control or
CGIYRLRSC peptide (100mM). At the indicated time points, cells were
fixed in glutaraldehyde, stained in crystal violet and solubilized in 10%
acetic acid. Cell growth was evaluated by absorbance at 590nm in
a microplate reader (Perkin Elmer, Waltham, MA).EMBO Mol Med (2012) 4, 1–20 SPR analyses
A BIAcore X instrument (GE-Healthcare, Milwaukee, WI) was used. To
study the interaction between a6 integrin and E-cadherin, the amine
coupling immobilization procedure was adopted. Briefly, the Fc-his-
tagged extracellular domain of E-cadherin (227nM) was allowed to
react with a CM5 sensor chip (GE-Healthcare) activated with a
mixture of 0.2M EDC and 0.5M NHS, leading to the immobilization of
11,830 Resonance Unit (RU) (corresponding to 0.134 pmoles/mm2) of
protein. Similar results were obtained for a reference chip coated with
Fc-his-tag-VEGFR2. Sensor chips were deactivated by injection of HCl–
ethanolamine. The his-tagged extracellular domain of a6b4 integrin
(100 nM) was injected over the E-cadherin surface for 4min in 10mM
Hepes pH 7.4 containing 0.15mM NaCl, 50mM EDTA, 0.005%
Surfactant P20, 1mM CaCl2, 1mM MgCl2 and 1mM MnCl2 (running
buffer), and then washed until dissociation. Because the sensor chip
could not be properly regenerated, we repeated this analysis on three
different, newly prepared E-cadherin-coated sensor chips to estimate
a Kd for the receptor interaction.
To study the interaction of a6 integrin and E-cadherin with
angiopoietin-like 6, NTA sensor chips (GE-Healthcare) were activated
with 500mM nickel solution, and either his-tagged protein was
injected over the activated surfaces to immobilize properly oriented
receptors. This procedure led to the immobilization of 1930 and
2000RU (10.2 and 22.5 fmoles/mm2) of protein for a6 integrin
and E-cadherin, respectively. A sensor chip saturated with nickel was
used as a reference. Angiopoietin-like 6 was injected over either sensor
chip for 4min in running buffer, and then washed until dissociation.
Following a procedure optimized for SPR analysis on decaying surfaces
(Joss et al, 1998), after each injection the sensor chips were subjected
to a new immobilization to obtain surfaces with unvarying receptor
density. Kd values were calculated from the overlay of sensorgrams
generated by injection of increasing concentrations of angiopoietin-
like 6, using the nonlinear fitting (single site model) software package
BIAevaluation 3.2 with a drifting baseline. Only sensorgrams whose
fitting values of 2 were <10 were considered in the analysis (Khalifa
et al, 2001).
Animal models
Experiments involving animals were reviewed and approved by the
Institute’s ethical committee, and by the Italian Ministry of Health.
Six-week female CD1-nude mice were purchased from Charles River
(Lecco, Italy). Animals were subjected to intraperitoneal anaesthesia
with a mixture of 0.75mg/ml xylazine (Xilor1, BIO98, Milan, Italy),
1mg/ml tiletamineþ1mg/ml zolazepam (Zoletil1, Virbac, Milan,
Italy), in physiological solution. After the mice were deeply anaes-
thetized, a midline incision was performed and target organs were
gently exposed. Two or five million suspended cells were injected in
50ml of culture medium intrasplenically (Giavazzi et al, 1986) or into
the median liver lobe (Kuo et al, 1995), respectively. To investigate a
pharmacological intervention on liver homing and/or colonization of
CRC cells, we randomized animals in two groups that received
medium alone (vehicle) or supplemented with 100mM CGIYRLRSC
peptide. The wound was closed by a double suture, and each animal
was given 0.1mg caprofen (Rymadil1, Pfizer, Milan, Italy) in a
physiological solution to allow post-operative pain relief and
rehydration. Mice were strictly monitored until completely awake,
and oral ampicillin was administered for 5 days after surgery. Mice2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 17
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The paper explained
PROBLEM:
CRC remains a leading cause of cancer death, mainly due to
metastatic spreading. New approaches are therefore urgently
needed to improve the management of patients with advanced
CRC.
RESULTS:
We here describe a molecular mechanism by which a physical
and functional interaction between a novel ligand/receptor pair
(angiopoietin-like 6 and a6 integrin/E-cadherin) contributes to
liver homing and colonization of human CRC cells. We also
describe an angiopoietin-like 6-mimicking peptide capable of
interfering with this interaction, thus acting as an antimetastatic
compound. We finally provide evidence for a correlation between
high levels of these molecules and poor prognosis in patients
with metastatic CRC.
IMPACT:
The identified metastasis binding, angiopoietin-like 6-mimicking
peptide can be the basis for the development of an antimeta-
static drug(s) with the potential to be translated into a clinical
trial. Furthermore, the coexpression of a6 integrin and
E-cadherin in CRC tissues can be exploited as a new prognostic
marker that could support physicians in evaluating diagnostic
and/or therapeutic interventions.
18were euthanized at the indicated time points, and organs were
photographed with a PL-200 digital photocamera (Samsung Electro-
nics, Milan, Italy). External metastatic areas were quantified by the use
of ImageJ software.
Bioinformatics
The frequency of peptide motifs was evaluated with ClustalW.
The protein Basic Local Alignment Search Tool (BLAST) was used
to investigate similarities between the metastasis-binding peptides
and the human proteome. To extract only the extracellular and
transmembrane proteins from the BLAST output dataset, Gene
Ontology_Cell Component (GO_CC) annotations were retrieved
through the DAVID Bioinformatics Resource Functional Annotation
tool (Huang da et al, 2009), searching for GOTERM_CC_ALL, with
default settings.
Statistical analyses
All the analyses were performed with Prism 5 software (GraphPad, La
Jolla, CA): two-way analysis of variance (ANOVA) followed by
Bonferroni’s post-test was used to evaluate differences within
treatments; t-test and Fisher’s exact test (two-tailed) were used to
compare selected experimental points; the Chi-squared test was used
to analyse contingency tables; survival curves were drawn as Kaplan–
Meier Cumulative Proportion Surviving graphs, and corresponding
p-values were calculated by the use of the log-rank (Mantel-Cox) test.
Asterisks indicate the following p-value ranges: p<0.05, p<0.01,
p<0.001.
For more detailed Materials and Methods see the Supporting
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